IMPACT OF THE BOTULINUM NEUROTOXIN INJECTIONS ON PATIENTS WITH DEPRESSION: THERAPEUTIC MECHANISMS AND POSSIBLE FUTURE PERSPECTIVE
DOI:
https://doi.org/10.52340/jecm.2024.05.19Keywords:
depression, botulinum neurotoxin, therapy, facial feedback, Beck Depression Inventory (BDI)Abstract
Background: Despite the fact that today's medicine is constantly developing in all directions, there are still some diseases that burden humanity and interfere with daily life, like Depression. Existing treatment tactics are often ineffective, and Botox injections in such cases are an experimental method.
Objectives: Our goal is to review previous researches and make this information available on a larger scale so that clinicians can access similar therapies for use in unconventional cases. The purpose of the study was not to directly cure depression, but to evaluate the positive impact that manipulations carried out for aesthetic purposes would have on their general mood and condition. Our attention was especially drawn to the fact that research on this topic has not been conducted in our country yet.
Methods: The study involved 15 participants and it lasted on average two months. The Beck Depression Inventory (BDI) Questionnaire, in total 21 question, was used for assessment, just like our predecessors.
Results: The results, to our delight, gave us very interesting feedback, based on which we can assume the positive contribution of Botox in the management of patients with depression. BoNT/A injections led to significant improvement of self-rated depression score by using Beck Depression Inventory (BDI). The response rates of BoNT/A were 34%. From the literature, we know that positive results in previous studies ranged from 13% to 52%.
Conclusion: Botulinum Neurotoxin therapy shows promise as a novel approach to treating depression. While further research is needed to establish its effectiveness, Botox may offer a unique and potentially valuable option for individuals struggling with depression.
Downloads
References
R.H. McAllister-Williams, C. Arango, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord, 267 (2020), 264-82
https://www.sciencedirect.com/science/article/pii/S0165032719321925
The 2019 Global Burden of Disease (GBD) study. https://vizhub.healthdata.org/gbd-results/
What is Electroconvulsive Therapy (ECT)? William McDonald, Laura Fochtmann et al. January 2023 https://www.psychiatry.org/patients-families/ect
Jennifer Coughlin, Ana Soule, Treatment-Resistant Depression, CRNP
Treatment-resistant depression-Sometimes depression doesn't get better, even with treatment. https://www.mayoclinic.org/diseases-conditions/depression/in-depth/treatment-resistant-depression/art-20044324
Thase M, et al. Unipolar depression in adults: Treatment of resistant depression. https://www.uptodate.com/home. Accessed March 1, 2021.
ECT, TMS and other brain stimulation therapies. National Alliance on Mental Illness. https://www.nami.org/Learn-More/Treatment/ECT,-TMS-and-Other-Brain-Stimulation-Therapies. Accessed March 1, 2021
Botulinum toxin (Botox) A for reducing the appearance of facial wrinkles: a literature review of clinical use and pharmacological aspect Bagus Komang Satriyasa
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489637/
Marc Axel Wollmer, Michelle Magid, Tillmann H. C. Kruger, Eric Finzi. Treatment of Depression with Botulinum Toxin
A Lagueny, P Burbaud. Mechanism of action, clinical indication and results of treatment of botulinum toxin.
Becky J Proskocil, Harmanjatinder S Sekhon, Yibing Jia, Valentina Savchenko, Randy D Blakely, Jon Lindstrom, Eliot R Spindel. Acetylcholine is an autocrine or paracrine hormone synthesized and secreted by airway bronchial epithelial cells
L. C. Bulnes, P. Mariën, M. Vandekerckhove, A. Cleeremans. The effects of Botulinum toxin on the detection of gradual changes in facial emotion
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6692314/
Jara Schulze, Insa Neumann, Michelle Magid, Eric Finzi, Christopher Sinke, M. Axel Wollmer, Tillmann H.C. Krüger. Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis.
https://www.sciencedirect.com/science/article/abs/pii/S0022395621000236
Toren P. Stearns, Mujeeb U. Shad, Gabriela C. Guzman, AA. Glabellar Botulinum Toxin Injections in Major Depressive Disorder: A Critical Review. https://www.psychiatrist.com/pcc/glabellar-botulinum-for-depression/
Nicole Washington, Hilary I. Lebow. Can Botox Help with Depression? on August 30, 2021. https://psychcentral.com/depression/botox-for-depression#next-steps
Botulinum Toxin Treatment for Depression: A New Paradigm for Psychiatry by Eric Finzi. https://www.mdpi.com/2072-6651/15/5/336
Jean-Paul Macher, Marc-Antoine Crocq, Treatment goals: response and nonresponse. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181789/#:~:text=Response%20to%20treatment%20supposes%20that,the%20initial%20score%20is%20significant.
Haim M. Solomon, Timothy Lilly, Jr. Bacteriological Analytical Manual (BAM) Main Page. Jan 2001.
Sven Söderkvist, Kajsa Ohlén, Ulf Dimberg. How the Experience of Emotion is Modulated by Facial Feedback https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5816132/
Andreas Hennenlotter, Christian Dresel, Florian Castrop, Andres O. Ceballos-Baumann, Afra M. Wohlschläger, Bernhard Haslinger. The Link between Facial Feedback and Neural Activity within Central Circuitries of Emotion—New Insights from Botulinum Toxin–Induced Denervation of Frown Muscles
https://academic.oup.com/cercor/article/19/3/537/429135?login=false
Kim, M.J.; Neta, M.; Davis, F.C.; Ruberry, E.J.; Dinescu, D.; Heatherton, T.F.; Stotland, M.A.; Whalen, P.J. Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: Preliminary findings from an A-B-A design. Biol. Mood Anxiety Disord. 2014, 4, 11.
Hyeon Joo Ham, In Jun Yeo, Seong Hee Jeon, Jun Hyung Lim, Sung Sik Yoo, Dong Ju Son, Sung-Su Jang, Haksup Lee, Seung-Jin Shin, Sang Bae Han, Jae Suk Yun, and Jin Tae Hong, Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724835/
Li, Y., Liu, T., & Luo, W. (2021). Botulinum Neurotoxin Therapy for Depression: Therapeutic Mechanisms and Future Perspective. Frontiers in Psychiatry, 12.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102733/
Lyu Alan FY, Lulu T, Xueyan G, Jing L, Yixian H, Xuping Z, et al. Clinical study on the efficacy and safety of botulinumtoxin A in the treatment of Parkinson′ s disease with depression. Chin J Neurol. (2019) 52:745–51.
Finzi E, Rosenthal NE. Treatment of depression with a botulinumtoxinA: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res. (2014) 52:1–6. doi: 10.1016/j.jpsychires.2013.11.006.
Chugh S, Chhabria A, Jung S, Kruger THC, Wollmer MA. Botulinum toxin as a treatment for depression in a real-world setting. J Psychiatr Pract. (2018) 24:15–20. doi: 10.1097/pra.0000000000000277
Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. J Cosmet Dermatol. (2009) 8:24–6. doi: 10.1111/j.1473-2165.2009.00419.x
MagidM, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. (2014) 75:837–44. doi: 10.4088/JCP.13m08845
Yogesh Dwivedi. Brain-derived neurotrophic factor: role in depression and suicide Neuropsychiatr Dis Treat. 2009; 5: 433–449. doi: 10.2147/ndt.s5700
Downloads
Published
How to Cite
Issue
Section
